Novo Nordisk expects the Food and Drug Administration (FDA) to decide on CagriSema in the fourth quarter of 2026, which ends on December 31. CagriSema is a fixed-dose combination of cagrilintide, a long-acting analog of the hormone amylin, and semaglutide, the GLP-1 receptor agonist in Ozempic and Wegovy. Novo filed its New Drug Application (NDA) for weight management in December 2025 and repeated the expected timing on November 14, 2026, when it presented the REDEFINE 9 trial at ObesityWeek.
FDA approved an amylin analog on its own, pramlintide (Symlin), in 2005. Novo has said CagriSema could be the first product combining an amylin analog with a GLP-1 receptor agonist to reach the market.
What FDA is reviewing
The application covers the combination at the highest dose Novo tested in its REDEFINE obesity program, for adults with obesity, or with overweight and at least one weight-related condition. Novo calls two Phase 3 trials, both published in The New England Journal of Medicine in 2025, the program's pivotal trials:
- REDEFINE 1 enrolled 3,417 adults with overweight or obesity and no diabetes. Body weight fell 20.4% with CagriSema versus 3.0% with placebo at 68 weeks, counting every participant randomized.
- REDEFINE 2 enrolled 1,206 adults with type 2 diabetes and overweight or obesity.
The cagrilintide page carries the full results of both trials, including how each analysis was run.
The trials since the filing
Since the filing, Novo has also reported Phase 3 trials that compared CagriSema with tirzepatide or tested it at lower doses.
- REDEFINE 4 (February 2026) compared CagriSema with tirzepatide at tirzepatide's highest dose in 809 adults with obesity, in an open-label trial over 84 weeks. Weight fell 20.2% with CagriSema and 23.6% with tirzepatide, counting participants whether or not they stayed on treatment, and the trial did not meet its primary endpoint of showing CagriSema non-inferior.
- REIMAGINE 5 (September 2026) compared a lower CagriSema dose with a lower tirzepatide dose in adults with type 2 diabetes. At 60 weeks, weight fell 12.4% with CagriSema versus 9.1% with tirzepatide, and the reduction in A1C (a measure of average blood sugar) was non-inferior, under Novo's efficacy estimand, which assumes everyone stayed on treatment.
- REDEFINE 9 (topline in September, full results in The Lancet Diabetes & Endocrinology on November 14) compared two lower CagriSema doses with placebo in 309 adults with overweight or obesity. At 68 weeks, weight fell 19.4% and 18.6% with the two doses versus 4.6% with placebo, counting participants whether or not they stayed on treatment.
The two tirzepatide comparisons used different doses and different populations, so their results do not conflict. Of these three trials, only REDEFINE 4 tested the dose Novo filed.
At ObesityWeek on November 16, Novo also presented post hoc analyses of bone measures from REDEFINE 1. In a substudy of 252 participants, bone mineral density measured by DXA scan fell with CagriSema, which Novo says is expected with substantial weight loss, and stayed within the normal range for age and sex at 68 weeks. A blood marker of bone breakdown rose modestly more with CagriSema than with semaglutide alone, despite the larger weight loss, and a marker of bone formation rose above its starting level. Novo notes that REDEFINE 1 was not designed to assess fracture risk and that longer follow-up would be needed to do so.
What approval would change for compounding
Cagrilintide is not eligible for compounding today. Section 503A of the Federal Food, Drug, and Cosmetic Act lets a state-licensed pharmacy compound from a bulk drug substance only if the substance meets one of three conditions:
- It complies with a United States Pharmacopeia (USP) or National Formulary monograph.
- If no monograph exists, it is a component of a drug FDA has approved.
- If neither applies, it appears on FDA's 503A bulk drug substances list.
Cagrilintide meets none of them. It has no monograph, is a component of no approved drug and does not appear among the substances nominated for the 503A list. Approval of CagriSema would make it a component of an approved drug, which satisfies the second condition.
That would not make compounded cagrilintide freely available. Section 503A also bars a pharmacy from compounding, regularly or in inordinate amounts, drug products that are essentially copies of a commercially available drug product, and every compounded drug must be for an identified individual patient with a valid prescription. Semaglutide, already a component of approved drugs, is the nearest precedent. FDA tied its tolerance of compounded semaglutide to the drug's shortage listing, which ended in February 2025, and the semaglutide page traces what changed after that.
Outsourcing facilities registered under section 503B have no component route at all. They can compound from a bulk drug substance only if it appears on FDA's 503B list of substances with a clinical need or if the drug is on FDA's shortage list, so approval by itself would not change cagrilintide's status under 503B.
What approval would not change
An approval covers Novo's product as filed. It would not approve cagrilintide on its own, which is in a separate Phase 3 program, RENEW, whose first trial is scheduled to reach primary completion in May 2027.
Research material sits outside it too. PeptideScouter indexes cagrilintide alone and in semaglutide + cagrilintide and retatrutide + cagrilintide blends, all sold for laboratory research use only. Whatever FDA decides, the decision applies to Novo's product as filed.
Sources
- Novo Nordisk, REDEFINE 9 results, November 14, 2026: REDEFINE 9 by analysis, the December 2025 NDA and the expected Q4 2026 decision.
- Novo Nordisk, bone analyses presented at ObesityWeek, November 16, 2026: the post hoc REDEFINE 1 bone analyses.
- Novo Nordisk, REIMAGINE 5 and REDEFINE 9 topline results, September 21, 2026.
- Novo Nordisk, REDEFINE 4 headline results, February 23, 2026.
- Garvey and colleagues, REDEFINE 1, New England Journal of Medicine, 2025.
- Davies and colleagues, REDEFINE 2, New England Journal of Medicine, 2025.
- Wharton and colleagues, REDEFINE 9, The Lancet Diabetes & Endocrinology, 2026.
- 21 U.S.C. 353a, pharmacy compounding (section 503A): the bulk drug substance conditions, the essential-copy limit and the prescription requirement.
- 21 U.S.C. 353b, outsourcing facilities (section 503B): the bulk drug substance conditions for outsourcing facilities.
Sources checked November 16, 2026.